Evotec AG has entered a strategic alliance with Forge Therapeutics to advance its Gram-negative antibiotic program targeting ‘LpxC’ for the treatment of bacterial infections including drug resistant ‘superbugs’. LpxC, an attractive antibacterial target however, a lack of suitable chemical starting points has impeded its progress. Forge has been applying its metal-binding pharmacophores (“MBP”) library and processes and has been able to identify potent drugable...